REGN's Eylea HD Shows Non-Inferiority to Eylea in Eye Disease Study
Portfolio Pulse from
Regeneron's phase III study shows that Eylea HD is non-inferior to the standard Eylea treatment in terms of visual gain for patients with retinal vein occlusion (RVO).
December 18, 2024 | 4:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron's Eylea HD has demonstrated non-inferiority to the standard Eylea treatment in a phase III study for RVO patients, potentially supporting its market position.
The successful phase III study result for Eylea HD suggests it could be a viable alternative to the standard Eylea treatment, potentially boosting Regeneron's market position and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100